Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 408

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 408
---
 by this proxy statement/prospectus and certain other legal matters related to this proxy statement/prospectus. Loeb & Loeb LLP has represented Liminatus in connection with the Business Combination.

### EXPERTS
The financial statements of Iris Acquisition Corp (formerly known as Tribe Capital Growth Corp I) as of December 31, 2023 and 2022, and for each of the two years in the period ended December 31, 2023, appearing in this proxy statement/prospectus have been audited by Marcum LLP, an independent registered public accounting firm, as set forth in their report thereon (which contains an explanatory paragraph relating to substantial doubt about the ability of Iris Acquisition Corp to continue as going concern as described in Note 1 to the financial statements) appearing elsewhere in this proxy statement/prospectus, and are included in reliance on such report given on the authority of such firm as an expert in accounting and auditing.

The consolidated financial statements of Liminatus Pharma, LLC and its subsidiaries as of December 31, 2023 and 2022, included in this proxy statement/prospectus have been audited by WithumSmith+Brown PC, an independent registered public accounting firm, as set forth in their report (which contains an explanatory paragraph relating to the substantial doubt about the ability of Liminatus Pharma, LLC to continue as a going concern as described in Note 1 to the financial statements) thereon appearing elsewhere in this proxy statement/prospectus, and are included in reliance on such report given on the authority of such firm as an expert in accounting and auditing.

<div align='center'>226</div>

TABLE OF CONTENTS

### APPRAISAL RIGHTS
There are no appraisal rights available to our stockholders in connection with the Business Combination.

### DELIVERY OF DOCUMENTS TO STOCKHOLDERS
Pursuant to the rules of the SEC, we and servicers that we employ to deliver communications to our stockholders are permitted to deliver to two or more stockholders sharing the same address a single copy of the proxy statement/prospectus. Upon written or oral request, we will deliver a separate copy of the proxy statement/prospectus to any stockholder at a shared address to which a single copy of the proxy statement/ prospectus was delivered and who wishes to receive separate copies in the future. Stockholders receiving multiple copies of the proxy statement/prospectus may likewise request that we deliver single copies of the proxy statement/prospectus in the future. Stockholders may notify